Course: Advances in Blood-based Biomarkers and Disease Modifying Anti-Amyloid Antibody Therapies for Early-Stage Alzheimer’s Disease
Released: 0000-00-00
Program Description
Click to Go to the Event Registration
This webinar provides an up-to-date, evidence-based information on pathophysiology, biomarkers, and disease-modifying drugs in treating Alzheimer’s disease (AD).
Agenda
Discuss the blood-based biomarkers in diagnosing early-stage Alzheimer's disease (AD) and its utility in the prevention – Gary Small, MD
Discuss clinical trial data on safety-efficacy profiles of approved and investigational disease-modifying anti-amyloid antibody therapies in managing early AD - Paul Schulz MD
Intended Audience
Neurologists, nurse practitioners, and physician assistants involved in Alzheimer’s disease patient care.
Commercial Supporter
Supported by an educational grant from Eisai, Inc.
Learning Objectives
Summarize the pathophysiology and the clinical presentation of Alzheimer’s disease (AD).
Assess the blood-based biomarkers in diagnosing early-stage AD and its utility in the prevention.
Identify strategies to optimize disease-modifying anti-amyloid antibody (AAA) therapies in managing patients with early-stage AD.
View Full Course